For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

Biotech veteran brings 20+ years of operations, facility design and manufacturing expertise Eric Hanson Industry veteran named Senior Director of Life Sciences at CRB Kansas City, Mo., Aug. 14, 2025 ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Xilio anticipates nominating development candidates for its PSMA program (ATACR format), CLDN18.2 program (ATACR format) and STEAP1 program (SEECR format) in the third quarter of 2025, fourth quarter ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...

According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from ...

Dr Hope Rugo explores how evolving endocrine strategies and targeted therapies are enhancing outcomes in hormone ...

Rising hopes of an interest-rate cut in September pushed US stocks higher on Wednesday, with the S&P 500 and Nasdaq both ...

During a live event, Mar discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.

Major indices were in the green early on Wednesday, with the S&P 500 and Nasdaq Composite building on yesterday's ...